Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

trametinib 1 pralsetinib 1 ponatinib 1 pembrolizumab 1 fludarabine phosphate 1 fludarabine 1 durvalumab 1 dabrafenib 1 Whole-Body Irradiation 1 Tacrolimus 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Mycophenolic Acid 1 Mesna 1 Melphalan 1 Immunotherapy 1 Gemcitabine 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1 Busulfan 1 Bone Marrow Transplantation 1 Biopsy 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡